Journal article
Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment
European journal of pharmaceutics and biopharmaceutics, Vol.183, pp.1-12
12/19/2022
DOI: 10.1016/j.ejpb.2022.12.011
PMCID: PMC10158852
PMID: 36549400
Abstract
Over the last decade, the potential for silver nanoparticles (AgNP) to be used as an anti-melanoma agent has been supported by both in vitro and in vivo evidence. However, an undesirably high concentration of AgNP is often required to achieve an antitumor effect. Therefore a combination treatment that can maintain or improve antitumor efficacy (with lower amounts of AgNP) while also reducing off-target effects is sought. In this study, the combination of AgNP and resiquimod (RSQ: a Toll-like receptor agonist) was investigated and shown to significantly prolong the survival of melanoma-challenged mice, when added sequentially. Results from toxicity studies showed that the treatment was non-toxic in mice. Immune cell depletion studies suggested the possible involvement of CD8
T cells in the antitumor response observed in the AgNP + RSQ (sequential) treatment. NanoString was also employed to further understand the mechanism underlying the increase in the treatment efficacy of AgNP + RSQ (sequential). Results showed significant changes in gene expression involving apoptosis and immune stimulation pathways when compared to the naïve group. In conclusion, the combination of AgNP and RSQ is a new combination worthy of further investigation in the context of melanoma treatment.
Details
- Title: Subtitle
- Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment
- Creators
- Supreeda Tambunlertchai - Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USASean M Geary - University of IowaYoussef W Naguib - Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USAAliasger K Salem - Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA. Electronic address: aliasger-salem@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- European journal of pharmaceutics and biopharmaceutics, Vol.183, pp.1-12
- DOI
- 10.1016/j.ejpb.2022.12.011
- PMID
- 36549400
- PMCID
- PMC10158852
- NLM abbreviation
- Eur J Pharm Biopharm
- ISSN
- 0939-6411
- eISSN
- 1873-3441
- Language
- English
- Date published
- 12/19/2022
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Dental Research; Chemical and Biochemical Engineering
- Record Identifier
- 9984345164602771
Metrics
11 Record Views